Journal of atherosclerosis and thrombosis最新文献_第7页

The Genetic Risk Score with Variants in PDGFs and PDGFRB for the Risk of Major Cardiovascular Adverse Events in Patients with Coronary Artery Disease. PDGFs和PDGFRB变异的遗传风险评分与冠状动脉疾病患者主要心血管不良事件的风险

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-04 DOI: 10.5551/jat.65369

Xiaojuan Xu, Wen Li, Fangyuan Liu, Changying Chen, Hankun Xie, Feifan Wang, Xu Han, Qian Zhuang, Xianghai Zhao, Junxiang Sun, Yunjie Yin, Pengfei Wei, Yanchun Chen, Song Yang, Chong Shen

{"title":"The Genetic Risk Score with Variants in PDGFs and PDGFRB for the Risk of Major Cardiovascular Adverse Events in Patients with Coronary Artery Disease.","authors":"Xiaojuan Xu, Wen Li, Fangyuan Liu, Changying Chen, Hankun Xie, Feifan Wang, Xu Han, Qian Zhuang, Xianghai Zhao, Junxiang Sun, Yunjie Yin, Pengfei Wei, Yanchun Chen, Song Yang, Chong Shen","doi":"10.5551/jat.65369","DOIUrl":"https://doi.org/10.5551/jat.65369","url":null,"abstract":"Aims: Previous studies have linked platelet-derived growth factors (PDGFs) and their receptor beta (PDGFRB) genetic variants to coronary artery disease (CAD), but their impact on major adverse cardiovascular events (MACEs) remains unclear.Methods: A cohort study of 3139 patients with CAD followed up until December 1, 2022 (median 5.42 years), genotyped 13 tagSNPs in PDGFs/PDGFRB pathway genes to establish weighted genetic risk scores (wGRS). Multiple Cox regression models analyzed the association of SNPs and wGRS with MACE outcomes using hazard ratios (HRs) and 95% confidence intervals (CIs). The wGRS improvement on traditional risk factors (TRFs) and the Global Registry of Acute Coronary Events (GRACE) score for MACEs were assessed using the C-statistic, net reclassification improvement (NRI), and integrated discrimination improvement (IDI).Results: Compared to low MACE-GRS (Q1 of quintile), high MACE-GRS (Q5 of quintile) had an increased risk of MACEs, with an adjusted HRs of 1.441 (P = 0.006). Compared to the TRF prediction model, the addition of MACE-GRS showed an improved discrimination with an NRI of 5.1% (95% CI, 0.7%-9.5%, P＜0.001) and IDI of 0.3% (95% CI, 0.0%-0.6%, P＜0.001). In addition, compared to the TRFs and GRACE score model, the addition of MACE-GRS showed an improved discrimination with an NRI of 5.1% (95% CI, 0.7%-9.6%, P＜0.001) and IDI of 0.3% (95% CI, 0.0%-0.5%, P＜0.001).Conclusions: Variants in the PDGF-PDGFRB pathway genes contribute to the risk of MACEs after CAD, and the wGRS might be able to serve as a risk predictor of MACEs in addition to TRFs.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transition of Metabolic Health Status and the Risk of Cardiovascular Diseases in a Japanese Population: the Hisayama Study. 日本人群代谢健康状况的转变和心血管疾病的风险：Hisayama研究

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-04 DOI: 10.5551/jat.65275

Mayu Higashioka, Satoko Sakata, Emi Oishi, Takanori Honda, Mao Shibata, Jun Hata, Takanari Kitazono, Haruhiko Osawa, Toshiharu Ninomiya

{"title":"Transition of Metabolic Health Status and the Risk of Cardiovascular Diseases in a Japanese Population: the Hisayama Study.","authors":"Mayu Higashioka, Satoko Sakata, Emi Oishi, Takanori Honda, Mao Shibata, Jun Hata, Takanari Kitazono, Haruhiko Osawa, Toshiharu Ninomiya","doi":"10.5551/jat.65275","DOIUrl":"https://doi.org/10.5551/jat.65275","url":null,"abstract":"Aims: To investigate the association between metabolic health status, defined by the combination of metabolic syndrome (MetS) and obesity, and cardiovascular disease (CVD) in a Japanese community.Methods: A total of 2,842 participants without prior CVD, aged 40 years or older, were followed up from 2007 until 2017. Participants were classified into 4 metabolic health statuses based on the presence of obesity (body mass index ≥ 25 kg/m2) and MetS: metabolically healthy normal weight (MHN) (obesity [-] and MetS [-]), metabolically unhealthy normal weight (MUN) (obesity [-] and MetS [+]), metabolically healthy obesity (MHO) (obesity [+] and MetS [-]), and metabolically unhealthy obesity (MUO) (obesity [+] and MetS [+]). The risk estimates were computed by using a Cox hazard regression analysis.Results: During the follow-up period, 190 participants developed CVD. The MUO group had a 1.94-times greater risk of developing CVD than the MHN group after adjusting for confounders, but no excess risk was observed in the MHO group. Moreover, in 1,595 participants who had undergone a health checkup in 2002, 5 years before baseline, the risk of developing CVD was 2.18-times greater in the group that transitioned from MHO to MUO and 1.75-times higher in the stable MUO group than in the stable MHN group, but was not higher in the stable MHO group.Conclusions: The present findings suggest that cardiovascular risk increases when metabolic abnormalities are present simultaneously with obesity. In individuals with obesity, it may be important to maintain metabolic health and/or lose weight to prevent CVD.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proteomic Analysis of Human Chylomicron Remnants Isolated by Apolipoprotein B-48 Immunoprecipitation. 用载脂蛋白 B-48 免疫沉淀法分离人乳糜微粒残渣的蛋白质组分析

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-01 Epub Date: 2024-07-31 DOI: 10.5551/jat.64920

Daisaku Masuda, Takeshi Okada, Masami Sairyou, Kazuaki Takafuji, Tohru Ohama, Masahiro Koseki, Makoto Nishida, Yasushi Sakata, Shizuya Yamashita

{"title":"Proteomic Analysis of Human Chylomicron Remnants Isolated by Apolipoprotein B-48 Immunoprecipitation.","authors":"Daisaku Masuda, Takeshi Okada, Masami Sairyou, Kazuaki Takafuji, Tohru Ohama, Masahiro Koseki, Makoto Nishida, Yasushi Sakata, Shizuya Yamashita","doi":"10.5551/jat.64920","DOIUrl":"10.5551/jat.64920","url":null,"abstract":"Aim: Postprandial hypertriglyceridemia (PHTG) is an independent risk factor for coronary heart diseases. PHTG exhibits accumulation of apoB-48 containing chylomicron remnants (CM-Rs) and apoB-100 containing VLDL remnants (VLDL-Rs), which are both known to be atherogenic. However, unlike VLDL-Rs, structural and functional characterization of CM-Rs remains to be elucidated due to challenges in separating CM-Rs from VLDL-Rs. Recently, we successfully isolated CM-Rs and VLDL-Rs utilizing anti-apoB-48 or apoB-100 specific antibodies. This study aimed to characterize the proteome of CM-Rs along with that of VLDL-Rs.Methods: Eight healthy subjects were enrolled. Venous blood was drawn 3 hours after high-fat-containing meals. We isolated CM-Rs and VLDL-Rs from sera through combination of ultracentrifugation and immunoprecipitation using apoB-48 or apoB-100 specific antibodies, followed by shotgun proteomic analysis.Results: We identified 42 CM-Rs or VLDL-Rs-associated proteins, including 11 potential newly identified proteins such as platelet basic protein (PPBP) and platelet factor 4, which are chemokines secreted from platelets. ApoA-I, apoA-IV, and clusterin, which are also known as HDL-associated proteins, were significantly more abundant in CM-Rs. Interestingly, apoC-I, which reduces the activity of lipoprotein lipase and eventually inhibits catabolism of remnant proteins, was also more abundant in CM-Rs. Moreover, we identified proteins involved in complement regulation such as complement C3 and vitronectin, and those involved in acute-phase response such as PPBP, serum amyloid A protein 2, and protein S100-A8, in both CM-Rs and VLDL-Rs.Conclusions: We have firstly characterized the proteome of CM-Rs. These findings may provide an explanation for the atherogenic properties of CM-Rs.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"226-238"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-HDL-C, Symptomatic Intracranial Arterial Stenosis, and Recurrent Vascular Risk in Minor Stroke. 非高密度脂蛋白胆固醇、症状性颅内动脉狭窄与轻微中风的复发性血管风险。

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-01 Epub Date: 2024-09-04 DOI: 10.5551/jat.64987

Haimei Fan, Tingting Liu, Kaili Zhang, Yongle Wang, Rong Wang, Fei Yang, Feifei Chen, Yanli Zhang, Huaai Guo, Xinyi Li, Xuemei Wu, Xiaoyuan Niu

{"title":"Non-HDL-C, Symptomatic Intracranial Arterial Stenosis, and Recurrent Vascular Risk in Minor Stroke.","authors":"Haimei Fan, Tingting Liu, Kaili Zhang, Yongle Wang, Rong Wang, Fei Yang, Feifei Chen, Yanli Zhang, Huaai Guo, Xinyi Li, Xuemei Wu, Xiaoyuan Niu","doi":"10.5551/jat.64987","DOIUrl":"10.5551/jat.64987","url":null,"abstract":"Aim: We aimed to assess the association between non-high-density lipoprotein cholesterol (non-HDL-C) and symptomatic intracranial artery stenosis (sICAS), as well as the impact of non-HDL-C on recurrent vascular events in patients with mild ischemic stroke ( NIHSS score ≤ 5).Methods: This prospective study was based on data from patients presenting within 72 hours of stroke occurrence. We included patients admitted to 8 Chinese hospitals between September 2019 and November 2021. The associations of non-HDL-C with sICAS and recurrent vascular risk were assessed using multivariate regression models and a restricted cubic spline analysis.Results: Among the 2,544 patients analyzed at 12 months, 652 (25.6%) were diagnosed with sICAS. Elevated non-HDL-C was linked to a higher incidence of sICAS, and the adjusted odd ratios for quintile variables and continuous variables were 1.36 ([95% CI, 1.01-1.81]) and 1.14 ([95% CI, 1.04-1.24). In comparison to those in the first quintile, the adjusted hazard ratio of the fifth quintile of non-HDL-C was 1.19 ([95% CI 0.78-1.80]) for recurrent ischemic stroke and was 0.39 ([95% CI, 0.17-0.91]) for intracranialhemorrhage.Conclusions: The non-HDL-C level may be a useful predictor of sICAS. Higher non-HDL-C levels may be associated with a lower risk of intracranial hemorrhage in mild, noncardiogenic stroke, but not a higher risk of recurrent ischemic stroke.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"141-162"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FIB-4 Index and Liver Stiffness Measurement are Potential Predictors of Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. FIB-4指数和肝脏硬度测量是代谢功能障碍相关性脂肪肝动脉粥样硬化的潜在预测指标

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-01 Epub Date: 2024-09-04 DOI: 10.5551/jat.64809

Yoshihito Kubotsu, Yoshiko Sakamoto, Motoko Tago, Atsuko Chihara, Misa Norita, Chika Inadomi, Kaori Inoue, Hiroki Takayanagi, Kenichi Tanaka, Hiroshi Isoda, Takuya Kuwashiro, Satoshi Oeda, Toshiyasu Shiratori, Keizo Anzai, Koichi Node, Hirokazu Takahashi

{"title":"FIB-4 Index and Liver Stiffness Measurement are Potential Predictors of Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Yoshihito Kubotsu, Yoshiko Sakamoto, Motoko Tago, Atsuko Chihara, Misa Norita, Chika Inadomi, Kaori Inoue, Hiroki Takayanagi, Kenichi Tanaka, Hiroshi Isoda, Takuya Kuwashiro, Satoshi Oeda, Toshiyasu Shiratori, Keizo Anzai, Koichi Node, Hirokazu Takahashi","doi":"10.5551/jat.64809","DOIUrl":"10.5551/jat.64809","url":null,"abstract":"Aims: Cardiovascular disease (CVD) is a common cause of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, CVD surveillance is important, but it is not well established. We evaluated the association between liver fibrosis, carotid artery atherosclerosis, and coronary artery stenosis in patients with MASLD.Methods: Overall, 153 patients with MASLD who underwent carotid artery ultrasound were enrolled. Maximum intima-media thickness including plaques (Max-IMT) was measured by ultrasound. To predict liver fibrosis, liver stiffness was measured by vibration-controlled transient elastography and the fibrosis 4 (FIB-4) index was calculated. Coronary computed tomography angiography was performed to detect coronary artery stenosis based on a Max-IMT of ≥ 1.1 mm.Results: The median Max-IMT was 1.3 mm, and 63 patients (41.2%) had a Max-IMT of ≥ 1.5 mm. FIB-4 index and liver stiffness was significantly correlated with Max-IMT, respectively (ρ=0.356, p＜0.001, ρ=0.25, p=0.002). Liver stiffness was significantly associated with a Max-IMT of ≥1.5 mm, independent of age. Individuals with higher FIB-4 index had moderate or severe coronary artery stenosis more frequently. Individuals with higher LSM level also had moderate or severe coronary artery stenosis more frequently, especially severe stenosis.Conclusions: Liver fibrosis parameters were associated with carotid artery atherosclerosis and coronary artery stenosis. Evaluation of liver fibrosis may be useful to identify significant atherosclerosis and coronary artery stenosis in patients with MASLD.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"239-252"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiplatelets for Cardiovascular Disease in Non-valvular AF with Rivaroxaban: A Subanalysis of the EXPAND Study. 使用利伐沙班治疗非瓣膜性房颤心血管疾病的抗血小板药物：EXPAND 研究的子分析。

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-01 Epub Date: 2024-09-28 DOI: 10.5551/jat.64681

Koichi Kaikita, Shinichiro Uchiyama, Hirotsugu Atarashi, Hiroshi Inoue, Takanari Kitazono, Takeshi Yamashita, Wataru Shimizu, Takanori Ikeda, Masahiro Kamouchi, Koji Fukuda, Hideki Origasa, Hiroaki Shimokawa

{"title":"Antiplatelets for Cardiovascular Disease in Non-valvular AF with Rivaroxaban: A Subanalysis of the EXPAND Study.","authors":"Koichi Kaikita, Shinichiro Uchiyama, Hirotsugu Atarashi, Hiroshi Inoue, Takanari Kitazono, Takeshi Yamashita, Wataru Shimizu, Takanori Ikeda, Masahiro Kamouchi, Koji Fukuda, Hideki Origasa, Hiroaki Shimokawa","doi":"10.5551/jat.64681","DOIUrl":"10.5551/jat.64681","url":null,"abstract":"Aim: In this subanalysis of the EXPAND study, we evaluated the risks and benefits of rivaroxaban plus antiplatelet therapy (APT) for patients with non-valvular atrial fibrillation (NVAF) complicated by stable coronary artery disease (CAD), ischemic stroke, or peripheral artery disease (PAD).Methods: From the EXPAND study population (n=7,141), patients with NVAF complicated by stable CAD (n=886), ischemic stroke (n=1,231), or PAD (n=160) were included. Patients complicated by any of them were set as ALL (n=2,030). Patients were all treated with rivaroxaban (10 or 15 mg/day) with (+) or without (-) APT. Efficacy outcomes were symptomatic stroke＋systemic embolism (SE), symptomatic stroke＋SE＋myocardial infarction＋cardiovascular death, and all-cause death. Safety outcomes included major and any bleeding. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for differences between the APT(+) and APT(-) groups.Results: There were no significant differences in the efficacy outcomes between the APT(+) and APT(-) groups in the ALL cohort or in the CAD and STROKE sub-cohorts. In the PAD subcohort, the HR [95% CI] for all-cause death in the APT(+) group increased (4.43 [1.05-18.71]; p=0.043). In the APT(+) group, the HR [95% CI] for any bleeding increased in the ALL cohort (1.28 [1.01-1.62]; p=0.044) and STROKE subcohort (1.42 [1.01-2.01]; p=0.047), and for major bleeding in the CAD subcohort (2.00 [1.01-3.93]; p=0.046).Conclusions: Rivaroxaban with APT did not reduce ischemic outcomes in patients with stable CAD or ischemic stroke; however, it did increase the risk of bleeding in patients with stable CAD or ischemic stroke.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"176-187"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study. 同时患有血脂异常和严重肾功能损害的患者服用培马贝特的药代动力学和安全性：4 期研究。

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-01 Epub Date: 2024-09-05 DOI: 10.5551/jat.64887

Shun Ishibashi, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Mao Watanabe, Michiko Nakanishi, Yuichi Makinose, Hideki Suganami, Yuji Kurihara, Shizuya Yamashita

{"title":"Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study.","authors":"Shun Ishibashi, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Mao Watanabe, Michiko Nakanishi, Yuichi Makinose, Hideki Suganami, Yuji Kurihara, Shizuya Yamashita","doi":"10.5551/jat.64887","DOIUrl":"10.5551/jat.64887","url":null,"abstract":"Aims: Per the package insert, pemafibrate was contraindicated for use in patients with severe renal impairment despite its biliary excretion. To validate this, we evaluated the pharmacokinetics and safety of pemafibrate for 12 weeks in patients with hypertriglyceridemia and renal impairment.Methods: In this phase 4, multicenter, placebo-controlled, double-blind, parallel-group, comparative study, 21 patients were randomly assigned to pemafibrate 0.2 mg/day or placebo within Groups A (estimated glomerular filtration rate [eGFR] ＜30 mL/min/1.73m2 without hemodialysis; pemafibrate n=4; placebo, n=2), B (hemodialysis; pemafibrate, n=4; placebo, n=1), and C (eGFR ≥ 30 and ＜60 mL/min/1.73m2 without hemodialysis; pemafibrate, n=8; placebo, n=2) for 12 weeks. Area under the concentration vs time curve within the dosing interval (τ) (AUCτ) of pemafibrate was measured after 12-week administration.Results: The AUCτ (geometric mean) of pemafibrate was 7.333 and 7.991 ng·h/mL in Groups A+B and C, respectively; in Groups A+B to C at 12 weeks, the geometric mean ratio of pemafibrate AUCτ was 0.92 (90% confidence interval [CI]: 0.62, 1.36). The upper limit of the 90% CI was ≤ 2.0 (predetermined criterion). There was no consistent trend in the AUCτ and maximum plasma concentration of pemafibrate with/without statin use. Renal impairment degree did not affect the incidence of adverse events. No safety concerns were observed.Conclusion: Pemafibrate repeated administration in patients with severe renal impairment did not increase pemafibrate exposure.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"210-225"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Clinical Implication of Pemafibrate, a Novel Selective PPARα Modulator. 新型选择性 PPARα 调节剂--培马贝特的临床意义

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-01 Epub Date: 2024-11-14 DOI: 10.5551/jat.ED275

Yoshio Fujioka

引用次数: 0

Atherosclerotic Diseases in Chronic Kidney Disease. 慢性肾脏病中的动脉粥样硬化疾病。

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-01 Epub Date: 2024-11-16 DOI: 10.5551/jat.RV22030

Toshiaki Nakano

引用次数: 0

Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial. 新型选择性 PPARα 调节剂--培马贝特对中国血脂异常患者的疗效和安全性：双掩蔽、随机、安慰剂和活性对照比较试验。

IF 3 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-02-01 Epub Date: 2024-08-02 DOI: 10.5551/jat.64112

Wenli Dai, Qiang Lv, Qingling Li, Lu Fu, Yawei Zhang, Yumin Zhang, Lijun Liu, Ryohei Tanigawa, Keisuke Kunitomi, Ryo Kamei, Hideki Suganami, Changsheng Ma

{"title":"Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial.","authors":"Wenli Dai, Qiang Lv, Qingling Li, Lu Fu, Yawei Zhang, Yumin Zhang, Lijun Liu, Ryohei Tanigawa, Keisuke Kunitomi, Ryo Kamei, Hideki Suganami, Changsheng Ma","doi":"10.5551/jat.64112","DOIUrl":"10.5551/jat.64112","url":null,"abstract":"Aims: Pemafibrate substantially lowers serum triglyceride (TG) levels and increases high-density lipoprotein cholesterol (HDL-C) levels primarily in Japan, but it has not been evaluated in China. We aimed to confirm the efficacy and safety of pemafibrate in Chinese patients with hypertriglyceridemia and low HDL-C levels by comparing placebo and fenofibrate.Methods: A multicenter, double-masked trial was conducted in China involving 344 patients with high TG and low HDL-C levels randomly assigned to one of four groups: pemafibrate 0.2 mg/d, pemafibrate 0.4 mg/d, fenofibrate 200 mg/d, or placebo for 12 weeks. The primary endpoint was the percentage change in fasting TG levels.Results: The percentage change in TG levels from baseline was -34.1%, -44.0%, -30.5%, and 6.5% in the pemafibrate 0.2 mg/d, pemafibrate 0.4 mg/d, fenofibrate 200 mg/d, and placebo groups, respectively. Pemafibrate 0.4 mg/d significantly reduced TG levels compared with that in both placebo (p＜0.0001) and fenofibrate groups (p=0.0083). Significant improvements in HDL-C, remnant cholesterol, and apolipoprotein A1 levels were also observed with both doses of pemafibrate than with the placebo. Pemafibrate showed significantly smaller changes in alanine aminotransferase, aspartate aminotransferase, and serum creatinine levels than those with fenofibrate.Conclusions: In Chinese patients, pemafibrate exhibited superior efficacy in improving TG levels and enhanced hepatic and renal safety compared to fenofibrate. Thus, pemafibrate may represent a promising therapeutic option for dyslipidemia in Chinese patients.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"125-140"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141889357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0